Vizsgálati helyszín
Diamond Clinic Sp. z o.o.
Cracow, 31-559, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 20lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 40 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis23 vizsgálat
- 2. fázis13 vizsgálat
- 2/3. fázis2 vizsgálat
- 4. fázis2 vizsgálat
- Állapot
- Lezárult20 vizsgálat
- Fut, nem toboroz12 vizsgálat
- Toboroz6 vizsgálat
- Még nem toboroz1 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Eli Lilly and Company10 vizsgálat
- Chiesi Farmaceutici S.p.A.5 vizsgálat
- Sanofi4 vizsgálat
- Incyte Corporation3 vizsgálat
- Amgen Inc.2 vizsgálat
- és még 15
Futó vizsgálatok
Toboroz
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
NCT07666490· 4. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Fut, nem toboroz
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019· 2. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma
2025-522640-41-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· 2/3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· 2. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Kymera Therapeutics, Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618· 3. fázis· Incyte Corporation· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228· 4. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Nektar Therapeutics· Forrás
Meghívásos bevonás
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· 2/3. fázis· Sanofi· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis
2023-503522-40-01· 2. fázis· Anaptysbio Inc.· Forrás
Lezárult
Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed treatment period of previous amlitelimab asthma clinical study
NCT06033833· 2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Lezárult
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
NCT06264674· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566· 3. fázis· Sanofi· Forrás
Lezárult
A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)
NCT05882877· 3. fázis· Amgen Inc.· Forrás
Lezárult
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
2022-502888-38-00· 2. fázis· Eli Lilly & Co.· Forrás
Fut, nem toboroz
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430· 3. fázis· Mineralys Therapeutics Inc.· Forrás
Lezárult
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT05916365· 3. fázis· Almirall, S.A.· Forrás
Lezárult
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)
2022-501586-50-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
NCT05421598· 2. fázis· Sanofi· Forrás
Lezárult
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Lezárult
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy
NCT04636814· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Lezárult
The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
NCT04636801· 3. fázis· Chiesi Farmaceutici S.p.A.· Forrás
Lezárult
A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis
2024-520057-20-00· 2. fázis· Bausch Health Americas Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· 3. fázis· Galderma R&D· Forrás
Lezárult
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
NCT03952559· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek